TDT 070
Skin Thermal Injuries
TDT-070 is being developed for the topical treatment of thermal injuries, e.g. radiation induced dermatitis and after-effects of photodynamic therapy, and other conditions where both analgesic and anti-inflammatory effects are required.
TDT-070 uses Transfersomes® to deliver ketoprofen, a well-established non-steroidal anti-inflammatory drug (NSAID) to the cutis (skin). Packaged as a spray, it targets skin conditions where a high local concentration of the drug is desirable without incurring the side effects of high-dose systemic administration of NSAIDs.
The initial target indications for TDT-070 are adjuvant treatments of radiation induced dermatitis (RID) and radiation-induced hardening of the skin, and subcutaneous tissue (fibrosis), seen especially in patients treated for carcinoma and head/neck cancer, and photodynamic therapy (PDT). Severe radiation dermatitis can be painful, may lead to infections, and can cause permanent scarring. No good therapy exists for these problems.
TDT-070 is expected to have advantages over oral non-steroidal anti-inflammatory drugs (NSAIDs), which only achieve insignificant drug concentrations in the skin. Both oral and conventionally applied topical NSAIDs can also cause side effects, particularly in the gastro-intestinal tract, even when taken for short-term use.
Market
Radiation induced dermatitis is a common side effect of radiation therapy. It has been estimated that 87 percent of all women undergoing radiation therapy for breast cancer will develop some degree of radiation dermatitis (Fisher J et al. 2000). The number of patients receiving PDT is growing steadily, and is expected to reach 600,000 in the USA by 2010.